Injectable anti-wrinkle treatment sales will strengthen through 2036, anchored by muscle relaxants at 20% of the type segment in 2026, driven by expanding clinical protocols and institutional procurement requirements. The market was valued at USD 5.1 billion in 2025 and is expected to be worth USD 13.43 billion by 2036.